AcelRx Pharmaceuticals Valuation

AcelRx Pharmaceuticals Investor Information

About 39.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. AcelRx Pharmaceuticals recorded a loss per share of 2.75. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 26th of October 2022. Based on the key indicators related to AcelRx Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, AcelRx Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.

AcelRx Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AcelRx Pharmaceuticals has an asset utilization ratio of 3.73 percent. This suggests that the Company is making $0.0373 for each dollar of assets. An increasing asset utilization means that AcelRx Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

AcelRx Pharmaceuticals Ownership Allocation

AcelRx Pharmaceuticals holds a total of 16.95 Million outstanding shares. 30% of AcelRx Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

AcelRx Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 1.77 M. Net Income was 47.76 M with loss before overhead, payroll, taxes, and interest of (3.34 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.